

Active Biotech and SmithKline Beecham agree to close collaboration regarding vaccines against traveller's diarrhoea

Active Biotech has taken back the worldwide rights for the ETEC vaccine project. The ongoing phase III clinical trials in Mexico and Guatemala are continuing according to plan. Alternative partnering strategies are under evaluation as well as the future clinical trials program.

Furthermore, all the international marketing rights for the SBL Cholera Vaccine have been transferred back to Active Biotech.

As part of the agreement, SmithKline Beecham's (SB) paediatric vaccines, currently sold by Active Biotech through SBL Vaccin under an agreement that were to expire 2003, will be transferred to the Nordic organisation of SB from 1 January 2001.

In line with Active Biotech's strategy to focus on vaccines for travellers, Active will receive a license for Sweden from SB regarding a second brand of their product HAVRIX, a vaccine to prevent hepatitis A infections. This product will be marketed by Active Biotech's Swedish marketing organisation SBL Vaccin.

These changes are not estimated to have any effect on the result of Active Biotech for the years 2000 –2001.

Lund 8 August 2000

Active Biotech (Publ)

Sven Andréasson
President & CEO

Active Biotech AB is a Swedish biotechnology company focused on the research and development of pharmaceuticals and vaccines, the core competence being knowledge of the human immune system. Active Biotech has a high quality project portfolio and considerable financial resources. Important products and projects include Dukoral, SBL Cholera Vaccine, a vaccine against traveller's diarrhoea (ETEC), innovative drugs against MS (SAIK) and cancer (TTS). The turnover of Active Biotech was SEK 267 million in 1999.

Active Biotech AB
Box 724, S-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46 19 20 50
E-mail info@activebiotech.com